HighTower Advisors LLC Reduces Holdings in CRISPR Therapeutics AG During Q4 2020: An Impactful Move on Nasdaq’s Innovative Powerhouses

HighTower Advisors LLC has recently demonstrated their position by implementing a significant reduction in their holdings in CRISPR Therapeutics AG during the fourth quarter of 2020. The assets managed by HighTower Advisors LLC show an astonishing decrease of 13.8% from the previous filing, resulting in a total of 30,512 shares. The net worth of these shares amounted to $1,231,000 according to the latest Form 13F filed with the Securities and Exchange Commission.

CRISPR Therapeutics AG is a company concentrated on developing gene-based medicines that are transformative for severe illnesses utilizing their proprietary CRISPR/Cas9 platform. This system enables specific genomic DNA modifications that result in very precise changes for gene editing. With numerous medical programs established across various disease areas such as oncology, hemoglobinopathies, rare diseases and regenerative medicine, CRISPR Therapeutics can handle different illnesses.

The stock market performance of this company reflects its groundbreaking and innovative design adequately. On Friday, CRSP opened at $64.66 with a PE ratio of -9.62 and a beta of 1.71 along with a market capitalization of $5.10 billion- which is quite impressive even by Nasdaq standards! Additionally, this stock’s positive run is evidenced by its newly achieved all-time high record of $86.95 and absolute low value of $38.94 over the past year alone.

Overall, HighTower Advisors LLC’s recent decision showcases how investors’ choices have an impact on companies like Crispr Therapeutics AG present in the Nasdaq big players pool- powerhouses that stand at the forefronts various scientific breakthroughs within many sectors relating to new technologies generated through new age advances as advancing scientific rigour as well as increased regulatory compliance opens up space for broader investment opportunities within different growth niches presently unfolding in this field globally – such as those that are predominantly driven but not limited to CRISPR therapeutics.

Investors Show Interest in CRISPR Therapeutics’ Gene-Editing Potential


CRISPR Therapeutics AG, a gene-editing company, has recently seen significant investment activity from institutional investors and hedge funds. For example, SG Americas Securities LLC increased its position in the company by 112.9% during Q4 2017, while WealthPlan Investment Management LLC acquired a new position in the company during Q3 2017. This follows recent news that CEO Samarth Kulkarni sold 25,000 shares of the business’s stock for $44.46 per share. CRISPR Therapeutics uses its proprietary CRISPR/Cas9 platform to develop gene-based medicines to address serious diseases like hemoglobinopathies, oncology, and rare diseases.

In May, the company announced quarterly earnings results that showed revenue of $100 million compared to analyst estimates of $24.33 million. The company also reported a negative net margin of 516.43% and a negative return on equity of 26.64%. Despite this performance, many analysts have assigned buy ratings to the stock and raised price targets. Citigroup even increased their target price from $55.00 to $70.00.

Although there has been some insider selling over the past three months, institutional investors still own over 71% of CRISPR’s outstanding shares. With a broad portfolio of therapeutic programs and cutting-edge technology at their disposal, CRISPR may continue to attract interested shareholders in the coming months and years ahead as it continues to push the boundaries of genetic medicine development.


Read more here: Source link